Page 67 - IACC Newsletter January 2013 Issue no. 8 HD

Basic HTML Version

conditions. Absorica is, therefore, not interchangeable and not substitutable with generic products of Accutane.
Absorica, NDA, was approved based on a large pivotal clinical trial enrolling 925 patients, the company said.
Ranbaxy Laboratories Inc. Senior Director Ashish Anvekar said, "We are most pleased to make Absorica available as a
valuable option for dermatologists and a subset of patients who suffer from severe recalcitrant nodular acne. Absorica
will be the flagship brand of the Ranbaxy dermatology product portfolio in the US."
Dell opens recycling collection centers to dispose electronics
The collection points will be spread across 13 Indian cities. PC maker Dell today said it has launched 16 electronics
recycling collection points for consumers across 13 cities in the country.
These collection points will be located at the existing Dell Carry-In Service (CIS) centers to encourage the responsible
disposal and recycling of any brand, through a Dell-approved environmental partner.
Dell’s electronics recycling collection points will be spread across 13 Indian cities - Ahmedabad, Bangalore, Chandigarh,
Chennai, Cochin, Gurgaon, Hyderabad, Jaipur, Lucknow and Noida, with two collection points each in Pune, Mumbai and
Each center will house collection bins that consumers can use to drop-off their non-working electronics. The electronics
recycling collection points are an extension of Dell’s global free recycling programme that aims to provide free and easy
recycling for consumers, keep environmentally sensitive materials out of landfills, enable materials to be recycled or
reused, and help conserve natural resources.
A Prem Ananth, Take Back Compliance Manager, Dell India said, “Dell has been working towards providing multiple
hassle-free options for disposing electronics responsibly and keeping them out of landfills. Our newest recycling
locations will now provide even more free and convenient options for consumers to recycle any brand of computer or
associated peripheral device.”
Aurobindo gets final nod from US FDA for anti-HIV drug
Abacavir is indicated as part of anti-retroviral combination therapy for treatment of HIV-infected adults and children.
Aurobindo Pharma Limited, a city-based manufacturer of generic pharmaceuticals and active pharmaceutical
ingredients, has received final approval from the US Food and Drug Administration (US FDA) to manufacture and market
the earlier tentatively-approved Abacavir tablets in 300 mg strength.
The product, which has been approved out of Aurobindo’s Unit-III formulations facility in Hyderabad, is ready for launch,
the company said.
The generic equivalent of ViiV Healthcare Company’s Ziagen tablets, Abacavir is indicated as part of anti-retroviral
combination therapy for the treatment of human immunodeficiency virus (HIV)-infected adults and children. The annual
sale of the product is approximately $88 million.
Aurobindo now has a total of 167 ANDA (abbreviated new drug application) approvals, including 141 final approvals
(including 2 from Aurolife Pharma LLC), and 26 tentative approvals from the US FDA.